Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report

Sanofi did a bit of Christmas Eve shopping this year, paying $2.2 billion to buy Dynavax and gain a marketed HBV vaccine and a clinical candidate for shingles.

On Dec. 24, the French pharma said it would pay $15.50 per share to acquire Dynavax Technologies Corp. (NASDAQ:DVAX), marking the third billion-dollar purchase by Sanofi (Euronext:SAN; NASDAQ:SNY) in 2025...